Trevi Therapeutics, Inc. TRVI Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies
Other financials
Where this comes from
Reported directly by Trevi Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Trevi Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Trevi Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Trevi Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation?
- Trevi Therapeutics, Inc. (TRVI) reported cash provided by (used in) financing activity, including discontinued operation of $222K in Q1 2026.
- How has Trevi Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
- Trevi Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation decreased by 97.4% year-over-year, from $8.71M to $222K.
- What is the long-term trend for Trevi Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation?
- Over 3 years (2021 to 2025), Trevi Therapeutics, Inc.'s cash provided by (used in) financing activity, including discontinued operation has grown at a 79.9% compound annual growth rate (CAGR), from $20.78M to $121.01M.
- What does cash provided by (used in) financing activity, including discontinued operation mean?
- This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.